Molecular surveillance of European quinolone-resistant clinical isolates of Pseudomonas aeruginosa and Acinetobacter spp. using automated ribotyping.
Nosocomial isolates of Pseudomonas aeruginosa and Acinetobacter spp. exhibit high rates of resistance to antibiotics and are often multidrug resistant. In a previous study (D. Milatovic, A. Fluit, S. Brisse, J. Verhoef, and F. J. Schmitz, Antimicrob. Agents Chemother. 44:1102-1107, 2000), isolates of these species that were resistant to sitafloxacin, a new advanced-generation fluoroquinolone with a high potency and a broad spectrum of antimicrobial activity, were found in high proportion in 23 European hospitals. Here, we investigate the clonal diversity of the 155 P. aeruginosa and 145 Acinetobacter spp. sitafloxacin-resistant isolates from that study by automated ribotyping. Numerous ribogroups (sets of isolates with indistinguishable ribotypes) were found among isolates of P. aeruginosa (n = 34) and Acinetobacter spp. (n = 16), but the majority of the isolates belonged to a limited number of major ribogroups. Sitafloxacin-resistant isolates (MICs > 2 mg/liter, used as a provisional breakpoint) showed increased concomitant resistance to piperacillin, piperacillin-tazobactam, ceftriaxone, ceftazidime, amikacin, gentamicin, and imipenem. The major ribogroups were repeatedly found in isolates from several European hospitals; these isolates showed higher levels of resistance to gentamicin and imipenem, and some of them appeared to correspond to previously described multidrug-resistant international clones of P. aeruginosa (serotype O:12) and Acinetobacter baumannii (clones I and II). Automated ribotyping, when used in combination with more discriminatory typing methods, may be a convenient library typing system for monitoring future epidemiological dynamics of geographically widespread multidrug-resistant bacterial clones.
Brisse
S
S
Eijkman-Winkler Institute, Utrecht University, 3584 CX Utrecht, The Netherlands. sbrisse@lab.azu.nl
Milatovic
D
D
Fluit
A C
AC
Kusters
K
K
Toelstra
A
A
Verhoef
J
J
Schmitz
F J
FJ
D042462:4-Quinolones; D000150:Acinetobacter / Q000145:classification / Q000187:drug effects / Q000235:genetics*; D000151:Acinetobacter Infections / Q000382:microbiology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001331:Automation; D003428:Cross Infection / Q000382:microbiology*; D004352:Drug Resistance, Microbial; D005060:Europe; D024841:Fluoroquinolones; D006801:Humans; D008826:Microbial Sensitivity Tests; D017720:Molecular Epidemiology / Q000379:methods; D010802:Phylogeny; D011552:Pseudomonas Infections / Q000382:microbiology*; D011550:Pseudomonas aeruginosa / Q000145:classification / Q000187:drug effects / Q000235:genetics*; D021521:Ribotyping / Q000379:methods; D013019:South Africa
D042462:4-Quinolones; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; C076246:sitafloxacin